Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1988-1-4
|
pubmed:abstractText |
This investigation was designed to study the effects of relatively low doses of cyclophosphamide (CY) on monocyte function in patients with surgically resected melanoma. Monocytes taken from patients 3 days after receiving 300 mg, 150 mg, or 75 mg CY/m2 had decreased interleukin-1 (IL-1) production. Production of tumor necrosis factor (TNF)-like molecules by the same monocytes appeared to be enhanced following 300 mg/m2 CY but not after 150 or 75 mg/m2 CY. In vitro studies of the direct effects of CY metabolites (mafosfamide and 4-hydroperoxycyclophosphamide) on human monocytes showed only concomitant decreases in production of IL-1 and TNF-like molecules. This occurred at concentrations that did not obviously affect viability, although monocyte spreading was inhibited. No evidence was obtained for in vitro enhancement of TNF-production. We conclude that CY can affect monocyte function. In vivo it may have both direct effects leading to decreased TNF and IL-1 production and indirect effects through lymphocytic or haematopoietic systems that activate monocytes to enhanced TNF production. The effects are dose-dependent. These CY-induced changes could be responsible in part for some of the alterations in host immunity and tumor resistance that follows administration of the drug.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-1,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/mafosfamide,
http://linkedlifedata.com/resource/pubmed/chemical/perfosfamide
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0741-5400
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
42
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
659-66
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:3500254-Combined Modality Therapy,
pubmed-meshheading:3500254-Cyclophosphamide,
pubmed-meshheading:3500254-Dose-Response Relationship, Drug,
pubmed-meshheading:3500254-Humans,
pubmed-meshheading:3500254-Immunity, Cellular,
pubmed-meshheading:3500254-Interleukin-1,
pubmed-meshheading:3500254-Leukocytes, Mononuclear,
pubmed-meshheading:3500254-Melanoma,
pubmed-meshheading:3500254-Tumor Necrosis Factor-alpha,
pubmed-meshheading:3500254-Vaccination
|
pubmed:year |
1987
|
pubmed:articleTitle |
Cyclophosphamide-induced alterations in human monocyte functions.
|
pubmed:affiliation |
Department of Radiation Oncology, University of California, Los Angeles 90024.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|